United Therapeutics Corp. (NASDAQ:UTHR) was up 3.1% on Wednesday . The company traded as high as $114.86 and last traded at $114.27, with a volume of 354,343 shares changing hands. The stock had previously closed at $110.87.

A number of brokerages recently issued reports on UTHR. Cowen and Company reiterated a “buy” rating on shares of United Therapeutics Corp. in a report on Thursday, April 28th. Zacks Investment Research lowered shares of United Therapeutics Corp. from a “strong-buy” rating to a “hold” rating in a report on Friday, July 8th. Argus lowered shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating and set a $114.00 price objective for the company. in a report on Tuesday, May 24th. Leerink Swann reiterated a “market perform” rating on shares of United Therapeutics Corp. in a report on Saturday, April 16th. Finally, HC Wainwright lowered shares of United Therapeutics Corp. from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $175.00 to $95.00 in a report on Wednesday, June 15th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $138.00.

The stock has a market capitalization of $5.02 billion and a PE ratio of 6.43. The stock has a 50-day moving average of $109.15 and a 200-day moving average of $118.04.

United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, April 28th. The biotechnology company reported $3.02 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.21 by $0.19. The company had revenue of $369 million for the quarter, compared to the consensus estimate of $395.02 million. During the same quarter last year, the business posted $2.55 EPS. The company’s revenue was up 12.7% compared to the same quarter last year. Equities research analysts forecast that United Therapeutics Corp. will post $14.17 earnings per share for the current year.

In related news, CEO Martine A. Rothblatt sold 1,261 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $120.79, for a total value of $152,316.19. Following the transaction, the chief executive officer now directly owns 1,501 shares in the company, valued at $181,305.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $110.00, for a total value of $330,000.00. Following the completion of the sale, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $330,000. The disclosure for this sale can be found here.

Other hedge funds have recently modified their holdings of the company. Schroder Investment Management Group raised its stake in shares of United Therapeutics Corp. by 1,423.0% in the fourth quarter. Schroder Investment Management Group now owns 377,300 shares of the biotechnology company’s stock valued at $59,089,000 after buying an additional 352,526 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of United Therapeutics Corp. by 2.9% in the fourth quarter. Principal Financial Group Inc. now owns 146,040 shares of the biotechnology company’s stock valued at $22,872,000 after buying an additional 4,184 shares in the last quarter. Bank of Montreal Can raised its stake in shares of United Therapeutics Corp. by 16.3% in the fourth quarter. Bank of Montreal Can now owns 167,241 shares of the biotechnology company’s stock valued at $26,191,000 after buying an additional 23,392 shares in the last quarter. Morgan Stanley raised its stake in shares of United Therapeutics Corp. by 8.1% in the fourth quarter. Morgan Stanley now owns 322,165 shares of the biotechnology company’s stock valued at $50,455,000 after buying an additional 24,130 shares in the last quarter. Finally, Legacy Capital Partners Inc. raised its stake in shares of United Therapeutics Corp. by 22.8% in the fourth quarter. Legacy Capital Partners Inc. now owns 8,350 shares of the biotechnology company’s stock valued at $1,308,000 after buying an additional 1,550 shares in the last quarter.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.